title: The timing of antiparkinsonian treatment reduction after subthalamic nucleus stimulation.
abstract: The objective of this work was to precisely analyse the reduction of the antiparkinsonian treatment in 18 consecutive patients with Parkinson's disease (PD) operated on for bilateral subthalamic nucleus (STN) stimulation, first after 1 month of follow-up, then at 1 year postoperatively. Trihexyphenidyle, selegiline, entacapone, apomorphine and lisuride could be withdrawn shortly after starting STN electrical stimulation. The levodopa mean daily dose was reduced by 57% at 1 month after surgery and remained stable at 1 year. The mean ropinirole and bromocriptine daily dose decrements after surgery corresponded to 54 and 63%, respectively, at 1 month and to 77 and 40% at 1 year. At 12 months postoperatively, one third of the patients no longer received any antiparkinsonian drugs and the others were on monotherapy of either levodopa or dopamine agonists or received a combined treatment of a dopaminergic agonist and levodopa. In conclusion, STN stimulation allows a major reduction and simplification of antiparkinsonian treatment which can usually be achieved during the early postoperative period.
authors.affiliation: Neurological Department D, Neurological Hospital Pierre Wertheimer, Lyon, France. stephane.thobois@chu-lyon.fr
authors.forename: S
authors.initials: S
authors.lastname: Thobois
authors.forename: S
authors.initials: S
authors.lastname: Corvaisier
authors.forename: P
authors.initials: P
authors.lastname: Mertens
authors.forename: C
authors.initials: C
authors.lastname: Di Guardo
authors.forename: H
authors.initials: H
authors.lastname: Mollion
authors.forename: M
authors.initials: M
authors.lastname: Guenot
authors.forename: F
authors.initials: F
authors.lastname: Rochefort
authors.forename: G
authors.initials: G
authors.lastname: Chazot
authors.forename: M
authors.initials: M
authors.lastname: Sindou
authors.forename: E
authors.initials: E
authors.lastname: Broussolle
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004599:Electric Stimulation Therapy; D004567:Electrodes, Implanted; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000503:physiopathology / Q000628:therapy*; D011182:Postoperative Care; D020531:Subthalamic Nucleus / Q000503:physiopathology*
chemical_list: D000978:Antiparkinson Agents